Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2020

01-10-2020 | Cancer Biomarker | Epidemiology

Diagnostic workup of early-stage breast cancer: can we choose more wisely?

Authors: Rona Aks, Shira Peleg Hasson, Ayelet Sivan, Tal Kohen, Larisa Rivo, Rinat Yerushalmi, Bella Kaufman, Amir Sonnenblick, Ido Wolf

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Login to get access

Abstract

Introduction

Current international guidelines, including the Choosing Wisely Initiative, recommends against the routine use of systemic imaging studies or tumor markers in early‐stage breast cancer. Accumulating data suggests that adherence to these guidelines is low. We aimed to investigate the execution of unnecessary diagnostic tests among Israeli breast cancer patients and identify factors associated with their performance.

Methods

A retrospective analysis was conducted involving a database of early breast cancer patients treated at Tel Aviv Sourasky Medical Center. A survey was distributed among Israeli surgeons and oncologists specializing in breast cancer treatment.

Results

The study included early breast cancer patients (n = 178), who have no indication for completing systemic evaluation. Nearly half of the patients (76, 42%) were referred to 128 unjustified diagnostic studies, with the most common referral comprising a PET-CT (n = 39 30.5%). As expected, none of the tests led to any change in either disease staging or alteration in clinical management. Variables associated with systemic evaluation included younger age (61.8% for < 50 years vs 38.9% for > 50 years, p = 0.02), diagnosis by palpable mass compared to screening mammography (26.9% vs 52.9% p = 0.043, respectively) and higher tumor grade (33.7% vs 52.2% p = 0.02, respectively). In concordance with the findings of the database, the physicians’ survey revealed low adherence to guidelines and a role of the treating physicians’ subjective feelings. Doctors were more likely to recommend unnecessary studies when presented with a clinical case as an image, than to an informative question.

Conclusions

Our data indicate a high rate of non-adherence to guidelines, physicians recommending extensive systemic evaluation for women with early breast cancer. These deviations from the guidelines are associated with subjective factors, some of them being physician-dependent. Initiatives aimed at improving adherence to guidelines, and specifically to guidelines recommending "doing less" should therefore include not just knowledge-based education but also encourage conversation about what is appropriate and necessary.
Appendix
Available only for authorised users
Literature
13.
go back to reference Podoloff DA, Advani RH, Allred C et al (2007) NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 5(Suppl 1):S1–22CrossRef Podoloff DA, Advani RH, Allred C et al (2007) NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 5(Suppl 1):S1–22CrossRef
19.
go back to reference Myers RE, Johnston M, Pritchard K et al (2001) Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 164:1439–1444PubMedPubMedCentral Myers RE, Johnston M, Pritchard K et al (2001) Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 164:1439–1444PubMedPubMedCentral
Metadata
Title
Diagnostic workup of early-stage breast cancer: can we choose more wisely?
Authors
Rona Aks
Shira Peleg Hasson
Ayelet Sivan
Tal Kohen
Larisa Rivo
Rinat Yerushalmi
Bella Kaufman
Amir Sonnenblick
Ido Wolf
Publication date
01-10-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05813-0

Other articles of this Issue 3/2020

Breast Cancer Research and Treatment 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine